MD Anderson Cancer Centre

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Metastatic breast cancer3 trials
• Colorectal cancer2 trials
• Chronic lymphocytic leukaemia1 trial
• Gastric and oesophageal cancer1 trial
• Head and neck cancer1 trial
• Hodgkin lymphoma1 trial
• Kidney cancer1 trial
• Lung cancer1 trial

Phase

• Phase 35 trials
• Phase 11 trial
• Phase 21 trial
• Phase 2/31 trial

Status

• Active, not recruiting4 trials
• Completed3 trials
• Terminated2 trials
• Recruiting1 trial

Lead sponsor

• Daiichi Sankyo4 trials
• ADVANCED MARKER DISCOVERY S.L.2 trials
• Eisai Inc.1 trial
• EMD Serono Research & Development Institute, Inc.1 trial
• Hutchmed1 trial
• and 1 more

Running trials

• Recruiting

  Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  NCT06731478· Phase 3· Daiichi Sankyo· Source

• Recruiting

  Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)

  NCT06295731· Phase 2/3· Inhibrx Biosciences, Inc· Source

  Contact: Study Director - Inhibrx

• Recruiting

  Development and Validation of a Blood Test for Early Diagnosis of Colorectal Cancer

  NCT06889883· ADVANCED MARKER DISCOVERY S.L.· Source

  Contact: Marta Jimenez

• Recruiting

  Observational Cross-reactivity Study for Colorectal Cancer Diagnosis

  NCT06889844· ADVANCED MARKER DISCOVERY S.L.· Source

  Contact: Marta Jimenez

• Active, not recruiting

  Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

  NCT02811861· Phase 3· Eisai Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Gastric and oesophageal cancer1 recruiting

Closed trials

• Terminated

  An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

  NCT03779113· Phase 1· Hutchmed· Source

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Daiichi Sankyo· Source

• Completed

  DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

  NCT03523585· Phase 3· Daiichi Sankyo· Source

• Terminated

  A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

  NCT03248492· Phase 2· Daiichi Sankyo· Source

• Completed

  Avelumab in First-line NSCLC (JAVELIN Lung 100)

  NCT02576574· Phase 3· EMD Serono Research & Development Institute, Inc.· Source